Integrated Filing — IndAS



General information about company
Scrip Code 532649
NSE Symbol NECLIFE
MSEI Symbol NOTLISTED
ISIN INE023H01027
Name of company Nectar Lifesciences Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2025
Date of end of financial year 31-Mar-2026
Date of board meeting when results were approved 14-Aug-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 11-Aug-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Single segment
Description of single segment Pharmaceutical Business Segment
Start date and time of board meeting 14-Aug-2025   15:00:00
End date and time of board meeting 14-Aug-2025   16:20:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 2806714000
Other income 3499000
Total income 2810213000
2 Expenses
(a) Cost of materials consumed 2360686000
(b) Purchases of stock-in-trade 0
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 274709000
(d) Employee benefit expense 242635000
(e) Finance costs 186952000
(f) Depreciation, depletion and amortisation expense 165157000
(f) Other Expenses
1 Other Expenses 547617000 547617000
Total other expenses 547617000
Total expenses 3777756000
3 Total profit before exceptional items and tax -967543000
4 Exceptional items 0
5 Total profit before tax -967543000
6 Tax expense
7 Current tax 0
8 Deferred tax -335235000
9 Total tax expenses -335235000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0
11 Net Profit Loss for the period from continuing operations -632308000
12 Profit (loss) from discontinued operations before tax 0
13 Tax expense of discontinued operations 0
14 Net profit (loss) from discontinued operation after tax 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0
16 Total profit (loss) for period -632308000
17 Other comprehensive income net of taxes 1000
18 Total Comprehensive Income for the period -632307000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 224261000
Face value of equity share capital 1
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations -2.82
Diluted earnings (loss) per share from continuing operations -2.82
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0
Diluted earnings (loss) per share from discontinued operations 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations -2.82
Diluted earnings (loss) per share from continuing and discontinued operations -2.82
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results
Textual Information(1) Notes:-tttt n1. The above financial results were reviewed by Audit Committee on August 14, 2025 and approved by the Board in its meeting held on August 14, 2025. The statutory auditors of the Company have conducted a “Limited Review” of the above standalone and consolidated unaudited financial results for the quarter ended on June 30, 2025. ntttt n2. The company is exclusively in the pharmaceutical business segment. ntttt n3. Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current period. ntttt n4. The figures of the last quarter for the previous financial year i.e. March 31, 2025 are the balancing figures between the audited figure in respect of the full previous financial year ended March 31, 2025 and the unaudited published year to date figures upto the third quarter ended December 31, 2024 which was subject to limited review and not audit. ntttt n5. The Company has undertaken following transactions after the end of the quarter: ni. Sale of business of manufacture, distribution, marketing and sale of active pharmaceutical ingredients and formulations (“Business”) of the Company to Ceph Lifesciences Private Limited (“Purchaser”) for INR 12,70,00,00,000/- (Indian Rupees one thousand two hundred seventy crore only) subject to adjustments in accordance with the terms of the business transfer agreement , as a slump sale on a going concern basis; and nii. Sale, transfer and delivery of the assets of the Company in relation to its menthol business (“Assets”) to Purchaser for INR 20,00,00,000/- (Indian Rupees Twenty Crores only), plus applicable GST payable on the sale of such Assets under the applicable law. ntttt n n



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2025
Date of end of reporting period 30-Jun-2025
Whether accounts are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2 Income tax relating to items that will not be reclassified to profit or loss 0
3 Amount of items that will be reclassified to profit and loss
1 Foreign Exchange Translation Reserve 2000 2000
Total Amount of items that will be reclassified to profit and loss 2000
4 Income tax relating to items that will be reclassified to profit or loss 1000
5 Total Other comprehensive income 1000